Studies have confirmed that mTOR inhibitor (everolimus) combined with trastuzumab reversed trastuzumab resistance via the hyperactivated PI3K-AKT-MTOR pathway due to PTEN deficiency in patients with HER2-positive advanced breast cancer [33]. Here, ERBB2 is linked to breast carcinoma.